Our History
utR Biotech Ltd. was founded in 2016 in Winnipeg, Manitoba, by David Petch, a visionary with over two decades of experience in biotechnology. Inspired by personal connections to diabetes and cancer, David embarked on a mission to revolutionize diabetes treatment by integrating C-peptide into insulin formulations—a concept that had the potential to address some of the most severe complications associated with the disease, including cardiovascular issues, neuropathy, Alzheimer’s, and cancer.
From its inception, utR Biotech set itself apart by focusing on innovative, affordable solutions tailored to low- and middle-income populations. With a passion for making life-saving therapies accessible worldwide, the company quickly grew into a pioneer in the biopharmaceutical industry.
Our journey began with extensive research and the development of a groundbreaking lyophilized insulin-C-peptide formulation. This innovative approach not only improves the shelf-life of insulin but also offers superior health benefits, particularly for underserved populations. The vision of creating transformative treatments has always been at the core of utR Biotech’s DNA.
Milestones:
- 2016: utR Biotech is founded with a bold vision to incorporate C-peptide into insulin formulations and improve the lives of insulin-dependent diabetics.
- 2018: Early concept studies validate the potential of C-peptide to mitigate secondary complications of diabetes.
- 2020: utR Biotech expands its research and development efforts, securing partnerships with leading researchers and institutions.
- 2023: Launch of a global initiative to provide affordable insulin therapies to low- and middle-income populations, positioning utR Biotech as a leader in global health innovation.
Driven by a commitment to innovation, collaboration, and social impact, utR Biotech continues to evolve. Today, we stand at the forefront of biotechnology, delivering life-changing therapeutics and striving toward a healthier, more equitable future for all.